466 related articles for article (PubMed ID: 26033215)
1. Inhibition of indoleamine 2,3-dioxygenase 1 expression alters immune response in colon tumor microenvironment in mice.
Takamatsu M; Hirata A; Ohtaki H; Hoshi M; Ando T; Ito H; Hatano Y; Tomita H; Kuno T; Saito K; Seishima M; Hara A
Cancer Sci; 2015 Aug; 106(8):1008-15. PubMed ID: 26033215
[TBL] [Abstract][Full Text] [Related]
2. IDO1 plays an immunosuppressive role in 2,4,6-trinitrobenzene sulfate-induced colitis in mice.
Takamatsu M; Hirata A; Ohtaki H; Hoshi M; Hatano Y; Tomita H; Kuno T; Saito K; Hara A
J Immunol; 2013 Sep; 191(6):3057-64. PubMed ID: 23956437
[TBL] [Abstract][Full Text] [Related]
3. 1-L-MT, an IDO inhibitor, prevented colitis-associated cancer by inducing CDC20 inhibition-mediated mitotic death of colon cancer cells.
Liu X; Zhou W; Zhang X; Ding Y; Du Q; Hu R
Int J Cancer; 2018 Sep; 143(6):1516-1529. PubMed ID: 29607498
[TBL] [Abstract][Full Text] [Related]
4. IDO1 metabolites activate β-catenin signaling to promote cancer cell proliferation and colon tumorigenesis in mice.
Thaker AI; Rao MS; Bishnupuri KS; Kerr TA; Foster L; Marinshaw JM; Newberry RD; Stenson WF; Ciorba MA
Gastroenterology; 2013 Aug; 145(2):416-25.e1-4. PubMed ID: 23669411
[TBL] [Abstract][Full Text] [Related]
5. Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors.
Koblish HK; Hansbury MJ; Bowman KJ; Yang G; Neilan CL; Haley PJ; Burn TC; Waeltz P; Sparks RB; Yue EW; Combs AP; Scherle PA; Vaddi K; Fridman JS
Mol Cancer Ther; 2010 Feb; 9(2):489-98. PubMed ID: 20124451
[TBL] [Abstract][Full Text] [Related]
6. Blockade of IDO-Kynurenine-AhR Axis Ameliorated Colitis-Associated Colon Cancer via Inhibiting Immune Tolerance.
Zhang X; Liu X; Zhou W; Du Q; Yang M; Ding Y; Hu R
Cell Mol Gastroenterol Hepatol; 2021; 12(4):1179-1199. PubMed ID: 34087454
[TBL] [Abstract][Full Text] [Related]
7. Synergistic antitumor effect with indoleamine 2,3-dioxygenase inhibition and temozolomide in a murine glioma model.
Hanihara M; Kawataki T; Oh-Oka K; Mitsuka K; Nakao A; Kinouchi H
J Neurosurg; 2016 Jun; 124(6):1594-601. PubMed ID: 26636389
[TBL] [Abstract][Full Text] [Related]
8. Ganoderic acid Me induces the apoptosis of competent T cells and increases the proportion of Treg cells through enhancing the expression and activation of indoleamine 2,3-dioxygenase in mouse lewis lung cancer cells.
Que Z; Zou F; Zhang A; Zheng Y; Bi L; Zhong J; Tian J; Liu J
Int Immunopharmacol; 2014 Nov; 23(1):192-204. PubMed ID: 25138378
[TBL] [Abstract][Full Text] [Related]
9. Indoleamine 2,3-dioxygenase (IDO) activity influence tumor growth in the TRAMP prostate cancer model.
Källberg E; Wikström P; Bergh A; Ivars F; Leanderson T
Prostate; 2010 Sep; 70(13):1461-70. PubMed ID: 20687219
[TBL] [Abstract][Full Text] [Related]
10. A novel cancer therapy by skin delivery of indoleamine 2,3-dioxygenase siRNA.
Yen MC; Lin CC; Chen YL; Huang SS; Yang HJ; Chang CP; Lei HY; Lai MD
Clin Cancer Res; 2009 Jan; 15(2):641-9. PubMed ID: 19147770
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of indoleamine 2,3-dioxygenase activity accelerates skin wound healing.
Ito H; Ando T; Ogiso H; Arioka Y; Saito K; Seishima M
Biomaterials; 2015 Jun; 53():221-8. PubMed ID: 25890721
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of increased indoleamine 2,3-dioxygenase activity attenuates Toxoplasma gondii replication in the lung during acute infection.
Murakami Y; Hoshi M; Hara A; Takemura M; Arioka Y; Yamamoto Y; Matsunami H; Funato T; Seishima M; Saito K
Cytokine; 2012 Aug; 59(2):245-51. PubMed ID: 22609210
[TBL] [Abstract][Full Text] [Related]
13. Indoleamine 2, 3-Dioxygenase: A Professional Immunomodulator and Its Potential Functions in Immune Related Diseases.
Heidari F; Ramezani A; Erfani N; Razmkhah M
Int Rev Immunol; 2022; 41(3):346-363. PubMed ID: 33118843
[TBL] [Abstract][Full Text] [Related]
14. The indoleamine-2,3-dioxygenase (IDO) inhibitor 1-methyl-D-tryptophan upregulates IDO1 in human cancer cells.
Opitz CA; Litzenburger UM; Opitz U; Sahm F; Ochs K; Lutz C; Wick W; Platten M
PLoS One; 2011; 6(5):e19823. PubMed ID: 21625531
[TBL] [Abstract][Full Text] [Related]
15. Indoleamine 2,3-dioxygenase regulates T cell activity through Vav1/Rac pathway.
Li R; Li H; Sun Q; Liu L; Zhang C; Ren X
Mol Immunol; 2017 Jan; 81():102-107. PubMed ID: 27930920
[TBL] [Abstract][Full Text] [Related]
16. Galectin 3 protects from cisplatin-induced acute kidney injury by promoting TLR-2-dependent activation of IDO1/Kynurenine pathway in renal DCs.
Volarevic V; Markovic BS; Jankovic MG; Djokovic B; Jovicic N; Harrell CR; Fellabaum C; Djonov V; Arsenijevic N; Lukic ML
Theranostics; 2019; 9(20):5976-6001. PubMed ID: 31534532
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells.
Brandacher G; Perathoner A; Ladurner R; Schneeberger S; Obrist P; Winkler C; Werner ER; Werner-Felmayer G; Weiss HG; Göbel G; Margreiter R; Königsrainer A; Fuchs D; Amberger A
Clin Cancer Res; 2006 Feb; 12(4):1144-51. PubMed ID: 16489067
[TBL] [Abstract][Full Text] [Related]
18. Research progress of indoleamine 2,3-dioxygenase inhibitors.
Jiang T; Sun Y; Yin Z; Feng S; Sun L; Li Z
Future Med Chem; 2015; 7(2):185-201. PubMed ID: 25686005
[TBL] [Abstract][Full Text] [Related]
19. Vascular expression, activity and function of indoleamine 2,3-dioxygenase-1 following cerebral ischaemia-reperfusion in mice.
Jackman KA; Brait VH; Wang Y; Maghzal GJ; Ball HJ; McKenzie G; De Silva TM; Stocker R; Sobey CG
Naunyn Schmiedebergs Arch Pharmacol; 2011 May; 383(5):471-81. PubMed ID: 21359968
[TBL] [Abstract][Full Text] [Related]
20. IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism.
Löb S; Königsrainer A; Zieker D; Brücher BL; Rammensee HG; Opelz G; Terness P
Cancer Immunol Immunother; 2009 Jan; 58(1):153-7. PubMed ID: 18418598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]